Chris Ryan

Ibrutinib plus venetoclax given at a fixed duration yielded favorable progression-free survival in patients with previously untreated, high-risk chronic lymphocytic leukemia and small lymphocytic lymphoma.

Olaparib and non-platinum chemotherapy produced similar overall survival results when treating patients with platinum-sensitive, relapsed ovarian cancer with BRCA mutations.

Olaparib maintenance therapy will be investigated after receiving first-line chemotherapy for patients with BRCA1/2 wild-type advanced ovarian cancer.

At a recent conference, Robert Dreicer, MD, MS, MACP, FASCO, offered his advice regarding the use of androgen deprivation therapy in patients with metastatic castration-sensitive prostate cancer.

Adding pembrolizumab to chemotherapy does not improve outcomes over chemotherapy alone in patients with advanced gastric or gastroesophageal junction adenocarcinoma, according to updated results of the KEYNOTE-062 trial.

Patients receiving hematopoietic stem cell transplantation appeared to have improved outcomes and a decreased incidence of acute graft-versus-host disease after being treated with itolizumab.

Patients with triple-class relapsed/refractory multiple myeloma treated with ciltacabtagene autoleucel saw a greater survival benefit over physician's choice of treatment.

Second-line treatment of lisocabtagene maraleucel demonstrated improved quality of life in patients with large B-cell lymphoma.

Ciltacabtagene autoleucel as a single infusion led to early, durable responses, and demonstrated positive minimal residual disease negativity for patients with multiple myeloma who had early clinical relapse.

Adding isatuximab to lenalidomide, bortezomib, and dexamethasone demonstrated a superior minimal residual disease rate in patients with transplant-eligible newly diagnosed multiple myeloma.

Tucatinib plus palbociclib and letrozole prolonged central nervous system progression-free survival for patients with hormone receptor–positive, HER2-positive breast cancer.

Positive response data were seen when patients with advanced or metastatic triple-negative breast cancer were treated with datopotamab deruxtecan.